A Study to Evaluate the Reduction in Sebum (Skin Oil) Induced by Clascoterone Cream 1% in Acne Patients

NCT06415279 | Completed Phase 4 Results FDA Drug

• 1 other identifier: DCS-67-22
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

The etiology of acne is heavily dependent on the production of sebum by the sebaceous glands that results in the growth of the bacteria c. acnes. If no sebum is present, there is no nutritional source for the c. acnes, the bacteria die, and acne resolves. An FDA approved acne medication consisting of clascoterone cream 1% is believed to effectively treat acne due to a decrease in sebum production. This mechanism of action has been postulated based on efficacy observed in the phase III trials that lead to its approval. This research aims to demonstrate the effect of clascoterone cream 1% in sebum reduction.

Conditions

Acne Vulgaris

Outcome Measures

Primary Outcomes (1)

• The Primary Efficacy Endpoint is the Change in Causal Sebum Measurements From the Forehead Obtained With a Sebumeter During the Study.

  The values represents the mean change from baseline. Casual sebum level is measured using a Sebumeter by means of grease-spot photometry. In this method, the measuring head of a cassette probe briefly exposes a section of a mat tape and brings it into contact with the sebum present on the surface of the forehead. As the tape absorbs sebum, it becomes increasingly transparent; conversely, lower levels of sebum result in less transparency. After contact, the tape is inserted into the device, which determines its transparency using a photocell-based light transmission measurement. The amount of transmitted light-reported in units from 0 to 350 µg/cm²-corresponds to the level of sebum present on the skin surface. The measurement has an estimated uncertainty of ±5%.

  Weeks 16

Secondary Outcomes (1)

• The Secondary Efficacy Endpoint is the Changes in the Facial Microbiome Induced by 12, and 52 Weeks of Clascoterone 1% Cream Application.

  Baseline, Week 12, and Week 52

Study Arms (1)

Winlevi (clascoterone) 1% cream

EXPERIMENTAL

Drug: Winlevi (clascoterone) 1% cream

Interventions

Winlevi (clascoterone) 1% cream DRUG

Twice daily (BID) dosing

Winlevi (clascoterone) 1% cream

Eligibility Criteria

• Age: 12 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Males and females 12+ years of age.
• Subjects with mild to moderate acne.
• Subjects must possess 10-100 total non-inflammatory lesions (open comedones and closed comedones), 10-50 total inflammatory lesions, no cysts, and up to 2 nodules (if deemed appropriate by the PI) on the face.
• Subjects with all Fitzpatrick skin types I-VI.
• Subjects who agree to use only the study products for acne treatment. No other medicated cleansers or moisturizers or acne treatments of any kind are allowed.
• Subjects agree not to introduce any new colored cosmetics or skin care products while participating in the study (lipsticks, eye shadows, facial foundations, blush, powder, cleansers, moisturizers).
• Subjects agree to arrive at all visits with a clean face, having washed his/her face and removed all facial and eye makeup products within 2 hours to 4 hours prior to the visit and is not to use/apply any topical facial product(s) until the visit is completed.
• No known medical conditions that, in the investigator's opinion, may interfere with study participation.
• Women of childbearing potential must be willing to use a form of birth control during the study. For the purpose of this study, the following are considered acceptable methods of birth control: oral contraceptives, Norplant, Depo-Provera, double barrier methods (e.g., condom and spermicide) and abstinence.
• Subjects are dependable and able to follow directions and willing to comply with the schedule of visits.
• Subjects in generally good physical and mental health.
• Able to read, write, speak, and understand English
• Individual (and/or his/her legally acceptable representative, as applicable) has signed the Consent for Photograph Release and ICD (and/or Assent Document, as applicable) including Health Insurance Portability and Accountability Act (HIPAA) disclosure.
• Subject must avoid sun exposure, or use sunscreen if sun exposure is unavoidable.
• Subject must avoid professional or facial spa procedures during the study.

You may not qualify if:

• Any dermatological disorder, which in the investigator's opinion, may interfere with the accurate evaluation of the subject's skin characteristics, except for the study condition of acne.
• Subjects who are not willing to use the assigned study product to their face as instructed.
• Subjects who have acne nodules/cysts representative of severe acne.
• Subjects who are currently using, planning to use during the study or has used any of the following in the specified time range (based on subject report):
• month prior to Visit 1: Prescription (oral or topically applied on the face) antibiotics, inhaled steroids (except those prescribed for allergies), or hormones (pre- or post-menopausal hormone-replacement therapy; insulin, etc.), or other medications that could make skin more sensitive or have an effect on the skin, as determined by the PI or designee. Oral contraceptives are acceptable.
• month prior to Visit 1: Prescription medication for acne (e.g. doxycycline, minocycline, clindamycin, sulfamethoxazole and trimethoprim \[Bactrim\], tetracycline, erythromycin, azithromycin, or Vibramycin®)
• month prior to Visit 1: Topical prescription retinoids (e.g. Retin-A®, Retin-A Micro®, Renova®, Adapalene, Tazarotene, Avita®, Tazorac®, Avage®, Differin®), azelaic acid, benzoyl peroxide, dapsone, sodium sulfacetamide, Epiduo®, or other similar prescription drug on the face
• months prior to Visit 1: Accutane or other oral retinoid
• weeks prior to Visit 1: Any of the following on the face:
• Light therapy
• OTC topical medications/products (including antiacne or antibacterial agents, topical anti-inflammatories, topical retinoids, etc.). Sunscreens (SPF) are acceptable.
• Females who are pregnant, lactating, or planning to become pregnant during the study or within 30 days of study completion. (Subject must document her response in either the source documentation or informed consent/assent forms).
• Subject has a surgery and/or invasive medical procedure planned during the study.
• Subject has observable suntan, scars, nevi, tattoo, excessive hair (including beard, mustache, or goatee), or other dermal conditions on the face that that could interfere with study evaluations or confound study results, as determined by the PI or designee.
• Subject is taking medications that would mask an adverse event (AE) or influence the study results, including:

Sponsors & Collaborators

• Sun Pharmaceutical Industries Limited: lead

Study Sites (1)

Dermatology Consulting Services, PLLC

High Point, North Carolina, 27262, United States

Location

Related Publications (1)

• Draelos ZD, Kyeremateng K, Squittieri N. Reduction in Facial Sebum Production Following Treatment with Clascoterone Cream 1% in Patients with Acne Vulgaris: 12-Week Interim Analysis. Dermatol Ther (Heidelb). 2025 Sep;15(9):2657-2666. doi: 10.1007/s13555-025-01495-y. Epub 2025 Jul 19.

  PMID: 40682762 DERIVED

MeSH Terms

Conditions

Acne Vulgaris

Interventions

Clascoterone

Condition Hierarchy (Ancestors)

Acneiform Eruptions; Skin Diseases; Skin and Connective Tissue Diseases; Sebaceous Gland Diseases

Results Point of Contact

• Title: Head-Regulatory Affairs
• Organization: Sun Pharmaceutical Industries Limited

Clinical.Trial@sunpharma.com

0226645

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 10, 2024
• First Posted: May 16, 2024
• Study Start: February 14, 2024
• Primary Completion: February 12, 2025
• Study Completion: February 12, 2025
• Last Updated: June 15, 2026
• Results First Posted: June 15, 2026

Record last verified: 2026-05

Locations

US (1)